Guangzhou Baiyunshan Pharmaceutical Holdings (874.HK) - Conservative About the Outlook
454 Views23 Dec 2021 09:10
This insight analyzed Baiyunshan’s 2021Q3 performance, the core business segments, the comparison with peers, the concerns on business transition, the outlook and the trading strategy for this stock.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- Porton Pharma Solutions (300363.CH) - Not Easy to Get into the First Tier04 Jan 2022
- China Healthcare Weekly (Dec.31)-1st State-Level Device Policy,TCM Guideline,TCM Rally Unsustainable02 Jan 2022
- Oral COVID-19 Antivirals and the Impact on China28 Dec 2021
- Guangzhou Baiyunshan Pharmaceutical Holdings (874.HK) - Conservative About the Outlook23 Dec 2021
- The CXO/Biotech Plunge and the Afterwards Investment Logic (2022)20 Dec 2021
- Pre-IPO HTDK Medical Holdings - Policy Risk Is the Biggest Uncertainty09 Dec 2021
- Pientzehuang Pharmaceutical Co., Ltd. (600436.CH) 2021Q3 - Concerns Behind The "Double Top Secret"25 Oct 2021
x